<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>ijesm</PublisherName>
      <JournalTitle>International Journal of Engineering, Science and</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>volume 15,issue 4</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>April 2026</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>0006</Year>
        <Month>04</Month>
        <Day>21</Day>
      </PubDate>
      <ArticleType>Engineering, Science and Mathematics</ArticleType>
      <ArticleTitle>Microemulsion-Based Transdermal Delivery of Ondansetron: Formulation Strategies, Characterization, and Therapeutic Applications</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>15</FirstPage>
      <LastPage>35</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Alok</FirstName>
          <LastName>Singh1*</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Madhaw</FirstName>
          <LastName>Kumar2</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>and Dr. O.P.</FirstName>
          <LastName>Verma3</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Microemulsion-based transdermal drug delivery systems have emerged as promising approaches for improving the therapeutic efficacy and bioavailability of drugs with poor oral absorption. Ondansetron hydrochloride, a selective 5-hydroxytryptamine type-3 (5-HT3) receptor antagonist widely used for the treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions, undergoes extensive first-pass hepatic metabolism, resulting in reduced oral bioavailability and frequent dosing requirements. Transdermal delivery offers an effective alternative by bypassing hepatic metabolism and providing sustained drug release.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>1.	Ondansetron; Microemulsion; Transdermal drug delivery; Skin permeation; Nanoformulation; Controlled release. OVERVIEW OF DRUG DELIVERY SYSTEM</Keywords>
      <URLs>
        <Abstract>https://ijesm.co.in/ubijournal-v1copy/journals/abstract.php?article_id=16227&amp;title=Microemulsion-Based Transdermal Delivery of Ondansetron: Formulation Strategies, Characterization, and Therapeutic Applications</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References/>
      </References>
    </Journal>
  </Article>
</ArticleSet>